Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01811-2
Affiliations:
32
Authors:
85
Go to article
Institutions Authors Share
HUTCHMED, China
3.000000
 0.09
Shanghai Chest Hospital, SJTU, China
2.000000
 0.06
Xiangya Hospital, CSU, China
2.000000
 0.06
Hunan Cancer Hospital, China
1.333333
 0.04
Central South University (CSU), China
1.333333
 0.04
Jilin Province Cancer Hospital, China
1.000000
 0.03
The First Affiliated Hospital of Nanchang University, China
1.000000
 0.03
Wuhan Union Hospital, HUST, China
1.000000
 0.03
State Key Laboratory of Translational Oncology, CUHK, China
1.000000
 0.03
Beijing Cancer Hospital / School of Oncology, PKUHSC, China
1.000000
 0.03
Cancer Institute and Hospital, CAMS & PUMC, China
1.000000
 0.03
Tumor Hospital of Guangxi Medical University, China
1.000000
 0.03
Shenzhen People’s Hospital, China
1.000000
 0.03
The First Hospital of China Medical University, China
1.000000
 0.03
Nanfang Hospital, China
1.000000
 0.03
Henan Cancer Hospital, ZZU, China
1.000000
 0.03
The First Affiliated Hospital, SYSU, China
1.000000
 0.03
Fujian Cancer Hospital, China
1.000000
 0.03
Sir Run Run Shaw Hospital (SRRSH), Zhejiang University School of Medicine, China
1.000000
 0.03
Shaanxi Provincial People's Hospital, China
1.000000
 0.03
First Affiliated Hospital, ZZU, China
1.000000
 0.03
Beijing Tuberculosis and Thoracic Tumor Institute / Beijing Chest Hospital, Capital Medical University, China
1.000000
 0.03
Anhui Chest Hospital, China
1.000000
 0.03
Sichuan Cancer Hospital, China
1.000000
 0.03
The First Affiliated Hospital of Xinxiang Medical University, China
1.000000
 0.03
Xiangyang Central Hospital, China
1.000000
 0.03
Taizhou Hospital of Zhejiang Province, China
0.500000
 0.02
Wenzhou Medical University (WMU), China
0.500000
 0.02
Second People's Hospital of Hunan, China
0.333333
 0.01
Interested in Oncology and Carcinogenesis?